DarioHealth Corp. (NASDAQ: DRIO) reported first-quarter 2026 revenue of $5.58 million, beating analyst expectations of $5.46 million. The company also reported a loss per share of $1.25, better than the consensus estimate for a loss of $1.48 per share.
DarioHealth is a digital health company that provides solutions for managing chronic conditions, including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its platform uses data analytics, coaching, connected devices, and its DarioIQ artificial intelligence layer to deliver personalized health interventions.
On May 13, 2026, DarioHealth reported financial results for the first quarter ended March 31, 2026. Revenue was $5.58 million, up from $5.2 million in the fourth quarter of 2025, marking the company’s second consecutive quarter of sequential revenue growth. However, revenue declined from $6.75 million in the same period last year, mainly because the prior-year quarter included $1.3 million in non-recurring pharmaceutical customer revenue.
The company continued to show progress in cost control. Operating expenses decreased to $10.5 million from $13.3 million a year earlier, a 21% year-over-year decline. Operating loss narrowed to $7.3 million from $9.4 million, representing a 22% improvement from the prior-year period.
DarioHealth reported a net loss of $8.2 million for Q1 2026, compared with a net loss of $9.2 million in Q1 2025. Basic and diluted loss per share was $1.25, compared with a loss per share of $2.87 in the prior-year period.
CEO Erez Raphael said the company is benefiting from its channel partner ecosystem, including Solera and Amwell, which provides access to more than 116 million covered lives. DarioHealth also said it added 10 new accounts during the quarter and had approximately $127 million in pipeline opportunities across 241 active potential opportunities.
From a balance-sheet perspective, DarioHealth ended the quarter with $20 million in cash and short-term deposits. Current assets were $28.7 million, while current liabilities were $9.4 million, implying a current ratio of about 3.1. The company had a long-term loan of $30.9 million and stockholders’ equity of $62.4 million, implying a debt-to-equity ratio of roughly 0.50. DarioHealth used $6.0 million in operating cash during the quarter, although that was an improvement from $6.7 million used in the prior-year period.
